Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus

  • News

Executive Summary

Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics

You may also be interested in...



Andrx’ Fortamet picks up exclusivity

Andrx' Fortamet (metformin extended-release) awarded three years of Waxman/Hatch marketing exclusivity, company says June 7. Fortamet launched in May; FDA approved Andrx' 505(b)(2) application for the antidiabetic agent April 27 (1"The Pink Sheet" May 3, 2004, p. 16)...

Andrx’ Fortamet picks up exclusivity

Andrx' Fortamet (metformin extended-release) awarded three years of Waxman/Hatch marketing exclusivity, company says June 7. Fortamet launched in May; FDA approved Andrx' 505(b)(2) application for the antidiabetic agent April 27 (1"The Pink Sheet" May 3, 2004, p. 16)...

Andrx Reviewing Brand Strategy Ahead Of Fortamet Launch

Andrx will launch diabetes agent Fortamet (metformin extended-release) as it is reducing emphasis on branded product development and marketing

Table

View full table

Tags:
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS043847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By